![Thomas Schulze](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Schulze
Fondateur chez FundaMental Pharma GmbH
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Hilmar Bading | M | - |
FundaMental Pharma GmbH
![]() FundaMental Pharma GmbH Pharmaceuticals: MajorHealth Technology FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016. | 8 ans |
Michel Briejer | M | - |
FundaMental Pharma GmbH
![]() FundaMental Pharma GmbH Pharmaceuticals: MajorHealth Technology FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016. | 2 ans |
Keno Gutierrez | M | - |
FundaMental Pharma GmbH
![]() FundaMental Pharma GmbH Pharmaceuticals: MajorHealth Technology FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016. | 2 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Wolfgang Barth | M | - |
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | 4 ans |
Stefan W. Henning | M | - |
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | - |
Thomas Fink | M | 52 |
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | 5 ans |
Heiko von der Leyen | M | - |
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | 1 ans |
Daniela Mauceri | M | - |
FundaMental Pharma GmbH
![]() FundaMental Pharma GmbH Pharmaceuticals: MajorHealth Technology FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Allemagne | 8 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Thomas Schulze
- Réseau Personnel